Header Logo

Connection

Gesine Meyer-Rath to Humans

Back to Details
This is a "connection" page, showing publications Gesine Meyer-Rath has written about Humans.
Gesine Meyer-Rath
Connection Strength
2,063
Humans
  1. Optimising HIV spending in eastern Europe and central Asia. Lancet HIV. 2024 Oct; 11(10):e654-e655.
    View in: PubMed
    Score: 0,072
  2. The cost of adding rapid screening for diabetes, hypertension, and COVID-19 to COVID-19 vaccination queues in Johannesburg, South Africa. BMC Public Health. 2024 Jul 16; 24(1):1900.
    View in: PubMed
    Score: 0,071
  3. A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme. Vaccine. 2024 Aug 13; 42(20):125988.
    View in: PubMed
    Score: 0,070
  4. Integration of point-of-care screening for type 2 diabetes mellitus and hypertension into the COVID-19 vaccine programme in Johannesburg, South Africa. BMC Public Health. 2023 11 20; 23(1):2291.
    View in: PubMed
    Score: 0,068
  5. Integration of point-of-care screening for type 2 diabetes mellitus and hypertension with COVID-19 rapid antigen screening in Johannesburg, South Africa. PLoS One. 2023; 18(7):e0287794.
    View in: PubMed
    Score: 0,066
  6. What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations. J Int AIDS Soc. 2023 07; 26 Suppl 2:e26106.
    View in: PubMed
    Score: 0,066
  7. The costs of interventions for type 2 diabetes mellitus, hypertension and cardiovascular disease in South Africa - a systematic literature review. BMC Public Health. 2022 12 12; 22(1):2321.
    View in: PubMed
    Score: 0,064
  8. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 12; 9(12):e857-e867.
    View in: PubMed
    Score: 0,063
  9. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
    View in: PubMed
    Score: 0,059
  10. Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa. Health Policy Plan. 2021 Nov 11; 36(10):1545-1551.
    View in: PubMed
    Score: 0,059
  11. Getting resources to those who need them: the evidence we need to budget for underserved populations in sub-Saharan Africa. J Int AIDS Soc. 2021 07; 24 Suppl 3:e25707.
    View in: PubMed
    Score: 0,057
  12. The cost and intermediary cost-effectiveness of oral HIV self-test kit distribution across 11 distribution models in South Africa. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,057
  13. The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,057
  14. The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity. Clin Infect Dis. 2021 05 04; 72(9):1642-1644.
    View in: PubMed
    Score: 0,057
  15. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. AIDS. 2020 05 01; 34(6):883-891.
    View in: PubMed
    Score: 0,053
  16. Primary healthcare delivery models for uninsured low-income earners during the transition to National Health Insurance: Perspectives of private South African providers. S Afr Med J. 2019 Sep 30; 109(10):771-783.
    View in: PubMed
    Score: 0,051
  17. Optimal HIV testing strategies for South Africa: a model-based evaluation of population-level impact and cost-effectiveness. Sci Rep. 2019 09 02; 9(1):12621.
    View in: PubMed
    Score: 0,051
  18. The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case. PLoS One. 2019; 14(2):e0210497.
    View in: PubMed
    Score: 0,049
  19. Targeting the right interventions to the right people and places: the role of geospatial analysis in HIV program planning. AIDS. 2018 05 15; 32(8):957-963.
    View in: PubMed
    Score: 0,046
  20. Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS One. 2017; 12(10):e0186557.
    View in: PubMed
    Score: 0,045
  21. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017; 12(10):e0186496.
    View in: PubMed
    Score: 0,045
  22. Cost-effectiveness of early identification of HIV infection. Lancet HIV. 2017 10; 4(10):e431-e432.
    View in: PubMed
    Score: 0,044
  23. Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health. 2017 01 31; 17(1):143.
    View in: PubMed
    Score: 0,042
  24. Prospects for HIV control in South Africa: a model-based analysis. Glob Health Action. 2016; 9:30314.
    View in: PubMed
    Score: 0,040
  25. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. PLoS Med. 2015 Sep; 12(9):e1001869.
    View in: PubMed
    Score: 0,038
  26. Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa. J Acquir Immune Defic Syndr. 2013 Mar 01; 62(3):322-328.
    View in: PubMed
    Score: 0,032
  27. Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS. 2013 Jan 14; 27(2):243-50.
    View in: PubMed
    Score: 0,032
  28. Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):e25-32.
    View in: PubMed
    Score: 0,032
  29. HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions. PLoS Med. 2012; 9(7):e1001247.
    View in: PubMed
    Score: 0,031
  30. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One. 2012; 7(5):e36966.
    View in: PubMed
    Score: 0,031
  31. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa. Sex Transm Dis. 2011 May; 38(5):401-9.
    View in: PubMed
    Score: 0,028
  32. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009 Nov; 21(11):1388-94.
    View in: PubMed
    Score: 0,026
  33. Reaching priority populations with different HIV self-testing distribution models in South Africa: an analysis of programme data. BMC Infect Dis. 2025 Feb 25; 22(Suppl 1):981.
    View in: PubMed
    Score: 0,019
  34. Transgender-Specific Differentiated HIV Service Delivery Models in the South African Public Primary Health Care System (Jabula Uzibone): Protocol for an Implementation Study. JMIR Res Protoc. 2024 Sep 13; 13:e64373.
    View in: PubMed
    Score: 0,018
  35. Costs of the COVID-19 vaccination programme: estimates from the West Rand district of South Africa, 2021/2022. BMC Health Serv Res. 2024 Jul 29; 24(1):857.
    View in: PubMed
    Score: 0,018
  36. Future HIV epidemic trajectories in South Africa and projected long-term consequences of reductions in general population HIV testing: a mathematical modelling study. Lancet Public Health. 2024 Apr; 9(4):e218-e230.
    View in: PubMed
    Score: 0,017
  37. Costs of distributing HIV self-testing kits in Eswatini through community and workplace models. BMC Infect Dis. 2024 Feb 29; 22(Suppl 1):976.
    View in: PubMed
    Score: 0,017
  38. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. AIDS. 2024 03 15; 38(4):589-594.
    View in: PubMed
    Score: 0,017
  39. A quantitative assessment of the consistency of projections from five mathematical models of the HIV epidemic in South Africa: a model comparison study. BMC Public Health. 2023 10 27; 23(1):2119.
    View in: PubMed
    Score: 0,017
  40. Acceptability, feasibility and cost of point of care testing for sexually transmitted infections among South African adolescents where syndromic management is standard of care. BMC Health Serv Res. 2023 Oct 10; 23(1):1078.
    View in: PubMed
    Score: 0,017
  41. Secondary distribution of HIV self-test kits by HIV index and antenatal care clients: implementation and costing results from the STAR Initiative in South Africa. BMC Infect Dis. 2023 Jun 01; 22(Suppl 1):971.
    View in: PubMed
    Score: 0,016
  42. Cost and outcomes of routine HIV care and treatment: public and private service delivery models covering low-income earners in South Africa. BMC Health Serv Res. 2023 Mar 11; 23(1):240.
    View in: PubMed
    Score: 0,016
  43. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 04; 10(4):e254-e265.
    View in: PubMed
    Score: 0,016
  44. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023 Feb; 11(2):e244-e255.
    View in: PubMed
    Score: 0,016
  45. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 09; 10(9):e1298-e1306.
    View in: PubMed
    Score: 0,016
  46. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 05; 9(5):e353-e362.
    View in: PubMed
    Score: 0,015
  47. Reduction in initiations of HIV treatment in South Africa during the COVID pandemic. BMC Health Serv Res. 2022 Mar 31; 22(1):428.
    View in: PubMed
    Score: 0,015
  48. Primary healthcare seeking behaviour of low-income patients across the public and private health sectors in South Africa. BMC Public Health. 2021 09 09; 21(1):1649.
    View in: PubMed
    Score: 0,015
  49. Costs of integrating HIV self-testing in public health facilities in Malawi, South Africa, Zambia and Zimbabwe. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,014
  50. Modelling costs of community-based HIV self-testing programmes in Southern Africa at scale: an econometric cost function analysis across five countries. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,014
  51. Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis. 2021 04 23; 223(8):1345-1355.
    View in: PubMed
    Score: 0,014
  52. Using HIV self-testing to increase the affordability of community-based HIV testing services. AIDS. 2020 11 15; 34(14):2115-2123.
    View in: PubMed
    Score: 0,014
  53. Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis. J Int AIDS Soc. 2019 07; 22(7):e25325.
    View in: PubMed
    Score: 0,013
  54. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2018 10 01; 79(2):195-205.
    View in: PubMed
    Score: 0,012
  55. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018 03; 21(3).
    View in: PubMed
    Score: 0,011
  56. Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study. PLoS One. 2017; 12(6):e0178249.
    View in: PubMed
    Score: 0,011
  57. Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints. PLoS Med. 2017 02; 14(2):e1002240.
    View in: PubMed
    Score: 0,011
  58. Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open. 2017 01 24; 7(1):e013908.
    View in: PubMed
    Score: 0,011
  59. Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
    View in: PubMed
    Score: 0,009
  60. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infect Dis. 2014 Jan 09; 14:14.
    View in: PubMed
    Score: 0,009
  61. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014 Jan; 2(1):e23-34.
    View in: PubMed
    Score: 0,009
  62. Impact and costs of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa. S Afr Med J. 2013 Jul; 103(7):436.
    View in: PubMed
    Score: 0,008
  63. Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis. PLoS One. 2013; 8(6):e67910.
    View in: PubMed
    Score: 0,008
  64. Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J. 2013 Jan 14; 103(2):101-6.
    View in: PubMed
    Score: 0,008
  65. Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study. PLoS Med. 2012; 9(8):e1001281.
    View in: PubMed
    Score: 0,008
  66. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health. 2012 Sep; 17(9):1142-51.
    View in: PubMed
    Score: 0,008
  67. Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa. Int J STD AIDS. 2009 Dec; 20(12):858-62.
    View in: PubMed
    Score: 0,006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.